Skip to main content
CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD. logo

CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD. — Investor Relations & Filings

Ticker · 000661 ISIN · CNE0000007J8 LEI · 300300X04OTKZG18WD66 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,288 across all filing types
Latest filing 2022-08-25 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 000661

About CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD.

https://ccht.jl.cn

CHANGCHUN HIGH-TECH INDUSTRY (GROUP) CO., LTD. is a diversified enterprise primarily focused on the research, development, production, and distribution of biopharmaceuticals and healthcare products. The company operates through several key subsidiaries, most notably GeneScience Pharmaceuticals, which specializes in recombinant human growth hormones and pediatric endocrinology treatments. Its product portfolio includes biological drugs, vaccines, and traditional Chinese medicines, targeting therapeutic areas such as growth disorders, infectious diseases, and oncology. The group emphasizes technological innovation and maintains a significant presence in the domestic market while expanding its international footprint. In addition to its core life sciences business, the company maintains interests in real estate development and infrastructure management.

Recent filings

Filing Released Lang Actions
2022年半年度财务报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as a "2022 年半年度财务报告" which translates to "2022 Semi-Annual Financial Report". It contains detailed financial statements including consolidated and parent company balance sheets, profit and loss statements, cash flow statements, and changes in equity for the half-year period ending June 30, 2022. The report explicitly states it is a half-year report and includes comprehensive financial data and analysis for the period, not just an announcement or summary. The document length is substantial (15,000 characters), and it is not a certification or a brief announcement. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2022
2022-08-25 Chinese
关于控股子公司GS3-007a口服液获得药物临床试验批准的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement from Changchun High-tech Industry Group Co., Ltd. regarding the approval of a clinical trial for a drug by its subsidiary. It is a regulatory announcement about a clinical trial approval from the National Medical Products Administration. The document does not contain financial data, management changes, voting results, or any report publication. It is a regulatory announcement related to drug approval and clinical trial status, which does not fit into financial report categories. Given the short length and nature, it fits best under Regulatory Filings (RNS) as a general regulatory announcement.
2022-08-19 Chinese
关于控股子公司重组人生长激素注射液新适应症获得《药品注册证书》的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Changchun High & New Technology Industry Group Co., Ltd. regarding the approval by the National Medical Products Administration (国家药品监督管理局) of an additional indication for a recombinant human growth hormone injection product by its controlling subsidiary. The content focuses on regulatory approval and product registration certificate issuance, which is a regulatory announcement related to product registration and compliance. It does not contain financial data, management changes, voting results, or financial performance information. The document is short (669 characters) and is an announcement of regulatory approval rather than a financial or management report. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2022-08-12 Chinese
关于控股子公司重组人生长激素注射液药品注册进展的提示性公告
Regulatory Filings Classification · 95% confidence The document is a short announcement from Changchun High & New Technology Industry Group Co., Ltd. regarding the progress of drug registration for a recombinant human growth hormone injection by its controlling subsidiary. It includes a regulatory update from the National Medical Products Administration about the issuance of drug approval documents. The document is brief (643 characters) and serves as a notification or progress update rather than a detailed financial or operational report. It does not contain financial statements, management discussion, or detailed regulatory filings like audit reports or annual reports. It is not a report publication announcement since it does not mention the release of a report but rather provides a regulatory progress update. The best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2022-08-04 Chinese
关于控股子公司EG017软膏获得药物临床试验批准的公告
Regulatory Filings Classification · 100% confidence The document is a short announcement from Changchun High-tech Industry Group Co., Ltd. regarding the approval of clinical trials for a drug (EG017 ointment) by the National Medical Products Administration. It contains no financial data, no report or financial results, and is primarily a regulatory announcement about a clinical trial approval. The document length is only 547 characters, indicating it is a brief announcement rather than a full report. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or any financial filings. It is best classified as a Regulatory Filing (RNS) as it is a general regulatory announcement about clinical trial approval and related risk disclosure.
2022-07-26 Chinese
深圳价值在线咨询顾问有限公司关于长春高新技术产业（集团）股份有限公司2022年限制性股票与股票期权激励计划调整及首次授予相关事项之独立财务顾问报告
Audit Report / Information Classification · 95% confidence The document is titled as an "Independent Financial Advisor Report" related to a 2022 restricted stock and stock option incentive plan adjustment and initial grant for Changchun High-tech Industry (Group) Co., Ltd. It contains detailed explanations of the incentive plan, approval procedures, grant conditions, performance targets, and other related financial and governance details. The content is a comprehensive advisory report prepared by an independent financial consultant, not a simple announcement or a brief summary. It is not a general annual report, earnings release, or regulatory filing. The document is focused on the stock incentive plan and includes detailed financial and procedural analysis, which fits the category of an Audit Report / Information (AR) as it involves financial advisory and verification related to a specific financial plan and its compliance with regulations. The length (15,000 characters) and detailed content confirm it is a full report, not just an announcement or certification. Therefore, the best classification is AR (Audit Report / Information). FY 2022
2022-07-25 Chinese

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.